A method for preventing or mitigating an acute allergic response in a subject is disclosed. The method includes a step of administering a nutritional composition to the subject. The nutritional composition includes at least one of an acidic or a neutral HMO, but does not include an N-acetyl-lactosamine.

The present invention relates to: an indole derivative, which is a novel cell mitosis inhibitor; a stereoisomer thereof or a pharmaceutically acceptable salt thereof; a use thereof as a therapeutic agent; a composition containing the same and a treatment method using the composition; and a preparation method therefor. According to the present invention, the indole derivative, the stereoisomer thereof or the pharmaceutically acceptable salt thereof, inhibits the tubulin polymerization during mitosis so as to induce apoptosis, and has an excellent anti-cancer effect also in cancer cells having multiple drug resistance.

The invention relates to a solid, particulate, urea-based composition comprising urea in particulate form and a urease inhibitor of the type phosphoric triamide, in particular N-(n-butyl) thiophosphoric triamide (nBTPT), wherein the urea-based composition is further characterized in that it comprises one or more alkaline or alkaline-forming inorganic compounds. The composition according to the invention has been stabilized against the degradation of a urease inhibitor of the type phosphoric triamide, in particular N-(n-butyl) thiophosphoric triamide (nBTPT) in the presence of urea. The invention further relates to a method for the manufacture of the claimed solid, particulate, urea-based composition.

Disclosed is an oleic acid derivative including a hydrophobic part C17H33 linked to a particular polar head part “A”, especially for use as a medicament, for instance, for the treatment of a disorder caused by the GPR120 receptor and/or the CD36 receptor, including administering to a subject in need thereof a therapeutically effective amount of the oleic acid derivative or of the pharmaceutical composition. Also disclosed is the use of the oleic acid derivative as a food composition.

A sweetening or sweetened composition includes sucrose, rubusoside or a rubusoside derivative, and a tannin which may be used in a process for preparing a beverage. Further disclosed is the use of the composition for sweetening beverages as well as for preparing a syrup as a precursor in the preparation of beverages and also as flavoring substance with modifying properties and for reducing the sucrose content in beverages without essentially exhibiting a reduced sweetness sensation. Also disclosed is the use of a combination comprising rubusoside or a rubusoside derivative and a tannin for shortening the lingering sweetness of artificial sweeteners and for shifting the onset of the temporal sweetness sensation of said artificial sweetener towards that of natural sugars.

A stable composition suitable for use as a sleep aid is described. The composition has, in combination: cannabinol, melatonin, magnesium glycinate, menaquinone, cholecalciferol, calcium, Vitamin E, L-Tryptophan, and gamma-aminobutyric acid.

The present invention relates to a prophylactic or inhibitory agent for brain hypofunction, which comprises a carotenoid composition or a carotenoid formulation, each containing astaxanthin, adonirubin and adonixanthin at a given ratio.

The present invention relates to a composition for preventing or treating neurodegenerative diseases or depression, containing a 2-amino-2-(1,2,3-triazole-4-yl)propane-1,3-diol derivative as an active ingredient and more specifically, to a pharmaceutical composition for preventing or treating neurodegenerative diseases or depression, containing, as an active ingredient, the compound having an effect of directly inhibiting ASM activity.

The present invention relates to a composition for treatment and/or prevention of neurodegenerative diseases comprising at least a vegetable extract, an amide of a fatty acid and, optionally, a natural amino acid.

Disclosed herein are pharmaceutical compositions and methods of treating prostate cancer including castrate resistant prostate cancer, metastatic castration resistant prostate cancer and non-metastatic castration resistant prostate cancer with an approved drug product containing an anti-androgen selected from the group consisting of enzalutamide, apalutamide and darolutamide.